NASDAQ:QNTM Quantum Biopharma (QNTM) Stock Price, News & Analysis $18.87 -1.12 (-5.60%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$19.40 +0.52 (+2.78%) As of 09/19/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Quantum Biopharma Stock (NASDAQ:QNTM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quantum Biopharma alerts:Sign Up Key Stats Today's Range$18.51▼$21.0050-Day Range$12.69▼$29.2152-Week Range$2.70▼$38.25Volume191,666 shsAverage Volume136,496 shsMarket Capitalization$72.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. Read More Quantum Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreQNTM MarketRank™: Quantum Biopharma scored higher than 7% of companies evaluated by MarketBeat, and ranked 922nd out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Quantum Biopharma. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Quantum Biopharma are expected to grow in the coming year, from ($3.27) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quantum Biopharma is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quantum Biopharma is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuantum Biopharma has a P/B Ratio of 4.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Quantum Biopharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.39% of the float of Quantum Biopharma has been sold short.Short Interest Ratio / Days to CoverQuantum Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuantum Biopharma does not currently pay a dividend.Dividend GrowthQuantum Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.39% of the float of Quantum Biopharma has been sold short.Short Interest Ratio / Days to CoverQuantum Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media1.9 / 5News Sentiment0.34 News SentimentQuantum Biopharma has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Quantum Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for QNTM on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows10 people have added Quantum Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Quantum Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.53% of the stock of Quantum Biopharma is held by insiders.Percentage Held by InstitutionsOnly 1.24% of the stock of Quantum Biopharma is held by institutions.Read more about Quantum Biopharma's insider trading history. Receive QNTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quantum Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNTM Stock News HeadlinesHealth Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive PerformanceSeptember 18 at 8:10 AM | globenewswire.comQuantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PTSeptember 12, 2025 | globenewswire.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.September 20 at 2:00 AM | Brownstone Research (Ad)Quantum BioPharma Receives BUY Rating from Kingswood Capital PartnersSeptember 10, 2025 | msn.comKingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price TargetSeptember 10, 2025 | globenewswire.comQuantum Group announces corporate updatesAugust 21, 2025 | msn.comWhy Is Quantum BioPharma In The News Today? Here’s An Important Update On Its Multiple Sclerosis Investigational DrugAugust 11, 2025 | msn.comQuantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis TrialAugust 11, 2025 | globenewswire.comSee More Headlines QNTM Stock Analysis - Frequently Asked Questions How have QNTM shares performed this year? Quantum Biopharma's stock was trading at $3.68 at the beginning of the year. Since then, QNTM shares have increased by 412.8% and is now trading at $18.87. How were Quantum Biopharma's earnings last quarter? Quantum Biopharma Ltd. (NASDAQ:QNTM) issued its earnings results on Wednesday, August, 6th. The company reported ($3.23) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $3.06. Who are Quantum Biopharma's major shareholders? Top institutional shareholders of Quantum Biopharma include AdvisorShares Investments LLC (1.27%) and Steward Partners Investment Advisory LLC (0.11%). How do I buy shares of Quantum Biopharma? Shares of QNTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quantum Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quantum Biopharma investors own include Jiuzi (JZXN), Aethlon Medical (AEMD), Aditxt (ADTX), Adial Pharmaceuticals (ADIL), Avalon GloboCare (ALBT), Ainos (AIMD) and AMC Entertainment (AMC). Company Calendar Last Earnings8/06/2025Today9/20/2025Next Earnings (Estimated)11/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:QNTM Previous SymbolNASDAQ:QNTM CIK1771885 Webwww.fsdpharma.com Phone416-854-8884FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($14.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-270.22% Return on Assets-131.87% Debt Debt-to-Equity RatioN/A Current Ratio0.78 Quick Ratio0.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.54 per share Price / Book4.16Miscellaneous Outstanding Shares3,820,000Free Float3,490,000Market Cap$72.08 million OptionableN/A Beta0.77 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:QNTM) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quantum Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quantum Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
